Vienna, Austria-based Marinomed has announced the granting of Chinese patent No. CN101678040, titled “Antiviral Polymer,” for a component of its Mavirex technology platform. According to the company, the patent covers prevention and treatment of the common cold using the polymer.
Marinomed’s Coldamaris nasal spray for the common cold is sold over the counter in the EU. That product is based on Carragelose, a polymer derived from seaweed.
Marinomed CEO Andreas Grassauer commented, “The national granting of this patent is an important further step in protecting Marinomed’s intellectual property and know-how around our anti-viral product portfolio based on our mavirex technology platform. Furthermore this patent contributes value in the out-licensing of our products or technology to partner companies in China.”
Read the Marinomed press release.
